October 14, 2025 08:05 ET | Source: Candel Therapeutics NEEDHAM, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc.…
24-month Phase I follow-up data show positive outcomes are maintained High levels of investigator and patient satisfaction, excellent safety profileOngoing registrational…
The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and…
Daniil Kvyat returns to the wheel of the #63 LMDh alongside Grosjean and Mortara at Road AtlantaSant’Agata Bolognese, 7 October…
– ARV-102 was well tolerated in clinical trials for both healthy volunteers and patients with Parkinson’s disease – – ARV-102…
OCALA, Fla., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that…
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral…
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101…
BENGALURU, India, Aug. 26, 2025 /PRNewswire/ -- Water is India's lifeline - and its looming crisis. With 80% of the…
YoY growth in Revenue and EBITDA of ~17% and ~94%, respectivelyOrder intake of INR 1,500+ Cr in Q1 FY26MUMBAI, India,…